Search

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved by the FDA, thanks to a clinical trial co-led by MSK.

… Thursday, November 21, 2024 On November 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to the drug zanidatamab (Ziihera ® ) to treat advanced and metastatic bile duct cancer (cholangiocarcinoma) and other biliary tract cancers that have high levels of a protein called HER2

Since its founding 19 years ago, the Gerstner Sloan Kettering Graduate School of Biomedical Sciences has attracted bright minds drawn to its connection to MSK. Learn more about how we're training tomorrow's leaders.

… Wednesday, November 12, 2025 It’s that time of year, when aspiring scientists across the nation and the world are deciding where to pursue their doctoral degrees in biomedical research. The competition is intense, and the decision is a major life commitment. The PhD, or Doctorate of Philosophy, is the

Memorial Sloan Kettering has convened a COVID-19 Operating Room Executive Committee to scrutinize all surgical cases and determine whether they were truly essential and to review needs, resources, and ICU availability.

… Monday, May 11, 2020 The COVID-19 pandemic has stressed healthcare systems globally and is presenting particular challenges to cancer surgeons and cancer surgery programs. As New York City quickly became the epicenter of the pandemic in the United States, Memorial Sloan Kettering convened an Operating

An MSK medical oncologist and geneticist discusses the latest drug approved for breast cancer and how genetic testing can lead to new treatments.

… Wednesday, February 21, 2018 Summary In this interview, Mark Robson, Chief of the Breast Medicine Service at Memorial Sloan Kettering, discusses olaparib, the latest drug approved for breast cancer, and how genetic testing can lead to new targeted therapies. Last month, the US Food and Drug Administration

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013 to expedite early-stage drug discovery of innovative new therapies. Under this expansion, Tri-I TDI will extend its current relationship with its industry partner, Takeda Pharmaceutical Company, Ltd. from the realm of small molecule discovery into the new research area of antibody drug discovery. All three institutions will benefit from Tri-I TDI’s expansion.

… Thursday, June 16, 2016 Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013 to expedite

New insights into the way cells break away from a tissue during embryonic development may also shed new light on the same process in the context of cancer metastasis.

… Wednesday, May 10, 2023 Cancer’s ability to spread throughout the body — a process known as metastasis — is responsible for the vast majority of cancer deaths. And a key feature of metastasis is that the cancer cells move, breaking away from a primary tumor and travelling to distant parts of the body

Research conducted in zebrafish shows that melanoma cells have an affinity for fat, and that eating it makes them more aggressive.

… Thursday, June 14, 2018 Summary Researchers at the Sloan Kettering Institute have discovered that melanoma cells in zebrafish use fat from nearby fat cells to fuel their growth and spread. Cancer cells get hungry. Very hungry. It takes a lot of energy to reproduce the way they do — repeatedly and often

German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.

… Thursday, December 1, 2011 Summary German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma. Cancer biologist Hans-Guido Wendel trained as a physician in Germany, but research

In these incredibly challenging times, healthcare workers are our real-life superheroes! Here at Memorial Sloan Kettering, our amazing staff is working around the clock to keep doing what we do best: providing safe and exceptional care to patients with cancer. From doctors and nurses to security, patient transporters, and cleaning staff, our entire team at MSK remains fiercely dedicated to our mission. 

… Thursday, April 16, 2020 In these incredibly challenging times, healthcare workers are our real-life superheroes! Here at Memorial Sloan Kettering, our amazing staff is working around the clock to keep doing what we do best: providing safe and exceptional care to patients with cancer. From doctors and

“We could not be more proud of this deserving group of the outstanding GSK students who have been recognized with fellowship support this academic year,” says GSK Dean Michael Overholtzer.

… Monday, October 25, 2021 Every year, the Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences awards fellowships to students who show promise in their scientific endeavors at GSK. These fellowships, which are based on academic excellence, are made possible by generous philanthropic gifts